Jul 16, 2026 08:01AM
Jul 16, 2026 08:00AM
Jun 18, 2026 02:37AM
Jun 16, 2026 06:09AM
Jun 15, 2026 09:00AM
May 8, 2026 03:38AM
May 8, 2026 02:45AM Oppenheimer Downgrades Engene Holdings Inc. (ENGN) to Perform
May 8, 2026 02:33AM
May 7, 2026 07:01AM
May 7, 2026 07:00AM
Apr 7, 2026 09:01AM
Apr 7, 2026 08:00AM
Mar 9, 2026 07:00AM
Jan 20, 2026 05:52PM enGene secures $125 million expanded debt facility with Hercules Capital
Jan 20, 2026 05:35PM
Dec 23, 2025 06:41AM
Dec 22, 2025 04:04PM
Dec 22, 2025 04:03PM
Dec 3, 2025 06:43AM
Dec 2, 2025 07:30AM
Dec 2, 2025 07:30AM enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
Nov 12, 2025 07:31AM
Nov 11, 2025 07:30AM
Nov 11, 2025 07:30AM
Nov 4, 2025 01:35PM
Sep 30, 2025 07:30AM
Sep 30, 2025 07:30AM
Sep 12, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)
Sep 11, 2025 04:03PM
Sep 3, 2025 07:30AM
Sep 3, 2025 07:30AM
Jul 8, 2025 08:03AM
Jul 8, 2025 08:00AM
Jun 25, 2025 08:00AM
Jun 25, 2025 08:00AM FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
Jun 16, 2025 06:40AM
Jun 12, 2025 08:00AM
May 28, 2025 07:30AM
May 28, 2025 07:30AM
Apr 29, 2025 04:18AM
Mar 10, 2025 04:05PM
Jan 30, 2025 08:00AM enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Inv
Jan 6, 2025 02:00PM
Dec 19, 2024 04:05PM
Sep 24, 2024 06:35AM
Jun 14, 2024 07:01AM
Nov 1, 2023 07:30AM

326,558 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All